HOUSTON, June 27, 2006 (PRIMEZONE) -- Endovasc, Inc. (OTCBB:EVSC) today announced that the Company has awarded Analytical Bio-Chemistry Laboratories, Inc. a contract to develop an assay to determine the content of Prostaglandin E-1 (PGE-1) in the blood of patients during and post delivery of Liprostin. The pharmakokinetic studies will be carried out in parallel with the Liprostin Phase III studies. Currently there is no validated analytical study on record in the U.S. to determine the concentration of both PGE-1 and its active metabolite at concentrations that Endovasc expects to see in the bloodstream.
"Our Liprostin liposome formulation was designed to slow the release of PGE-1 and thereby maintain a low, biologically active level of the drug in the body for an extended period of time. Normally, an intravenous injection of free PGE-1 is metabolized within 90 seconds as it passes through the lungs. This study will measure the release rate of PGE-1 from the liposome into the bloodstream," said Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer.
Endovasc's Liprostin is a liposome-encapsulated form of Prostaglandin E-1 (PGE-1) which is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. Endovasc has submitted its protocol for a phase IIIa clinical trial of Liprostin for the treatment of intermittent claudication, a symptom of Peripheral Arterial Disease, to the FDA. Intermittent claudication causes a cramping sensation in the legs that is present during exercise or walking and occurs as a result of decreased oxygen supply.
About Analytical Bio-Chemistry Laboratories, Inc.:
Analytical Bio-Chemistry Laboratories, Inc., is a contract research and development company that provides analytical and biological services in support of U.S. and global product registrations for the pharmaceutical industry. Established in 1968, the company provides scientific consulting, custom synthesis, in-vitro/in-vivo services, pharmacokinetics, bio-analysis, and a full spectrum of cGMP analytical services. Through partnerships and industry alliances, ABC Labs provides unparalleled service and depth of experience that helps accelerate IND and NDA submissions and minimize time to market. For more information please visit www.abclabs.com.
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal-based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing a stent coating technology; and Nutraceutical Development Corporation.
For more information about Endovasc, please visit www.endovasc.com.
Safe Harbor:
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.